Clinical Trial: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Clinical Trial: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Sponsor and Collaborators

Singapore General Hospital

Contact
Contact: Daryl Tan, MBBS MRCP
65-63266604
daryl.tan@sgh.com.sg

Contact: Pei Woon ZN Eng, Bsc (hons)
65-63214627
eng.pei.woon@sgh.com.sg

Principal Investigator
Daryl Tan, MBBS MRCP Singapore General Hospital

ClinicalTrials.gov Identifier
NCT00901147
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs